University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Selected Publication:

Open Access Logo

Type of publication: Journal Article
Type of document: Full Paper

Year: 2018

Authors: Schmidt, S; Schumacher, N; Schwarz, J; Tangermann, S; Kenner, L; Schlederer, M; Sibilia, M; Linder, M; Altendorf-Hofmann, A; Knösel, T; Gruber, ES; Oberhuber, G; Bolik, J; Rehman, A; Sinha, A; Lokau, J; Arnold, P; Cabron, AS; Zunke, F; Becker-Pauly, C; Preaudet, A; Nguyen, P; Huynh, J; Afshar-Sterle, S; Chand, AL; Westermann, J; Dempsey, PJ; Garbers, C; Schmidt-Arras, D; Rosenstiel, P; Putoczki, T; Ernst, M; Rose-John, S

Title: ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

Source: J Exp Med. 2018; 215(4):1205-1225

Authors Vetmeduni Vienna:

Kenner Lukas
Tangermann Simone

Vetmed Research Units
Institute of Pathology, Pathology of Laboratory Animals

Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R), but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in the absence of ADAM17, tumorigenesis was almost completely inhibited, and the few remaining tumors were of low-grade dysplasia. RNA sequencing analysis demonstrated down-regulation of STAT3 and Wnt pathway components. Because EGF-R on myeloid cells, but not on intestinal epithelial cells, is required for intestinal cancer and because IL-6 is induced via EGF-R stimulation, we analyzed the role of IL-6 signaling. Tumor formation was equally impaired in IL-6-/- mice and sgp130Fc transgenic mice, in which only trans-signaling via soluble IL-6R is abrogated. ADAM17 is needed for EGF-R-mediated induction of IL-6 synthesis, which via IL-6 trans-signaling induces β-catenin-dependent tumorigenesis. Our data reveal the possibility of a novel strategy for treatment of colorectal cancer that could circumvent intrinsic and acquired resistance to EGF-R blockade.© 2018 Crown copyright. The government of Australia, Canada, or the UK ("the Crown") owns the copyright interests of authors who are government employees. The Crown Copyright is not transferable.

Keywords Pubmed: ADAM17 Proteindeficiencymetabolism
Adenomatous Polyposis Colimetabolism
Cell Line, Tumor
Cell Nucleusmetabolism
Colorectal Neoplasmsgeneticsmetabolismpathology
Disease Models, Animal
ErbB Receptorsmetabolism
Gastrointestinal Microbiome
Gene Expression Regulation, Neoplastic
Intestinal Neoplasmsgeneticsmetabolismpathology
Intestine, Smallpathology
Ki-67 Antigenmetabolism
Mice, Inbred C57BL
Neoplasm Metastasis
Neoplasm Staging
RNA, Messengergeneticsmetabolism
STAT3 Transcription Factormetabolism
Signal Transduction
Tumor Burden
beta Cateninmetabolism

© University of Veterinary Medicine ViennaHelp and DownloadsAccessibility statement